Home/Filings/4/0001209191-21-025756
4//SEC Filing

RASMUSSEN HENRIK S MD 4

Accession 0001209191-21-025756

CIK 0001564824other

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 8:00 PM ET

Size

21.2 KB

Accession

0001209191-21-025756

Insider Transaction Report

Form 4
Period: 2021-04-01
RASMUSSEN HENRIK S MD
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2021-04-06$111.68/sh10,000$1,116,800101,819 total
  • Sale

    Common Stock

    2021-04-01$114.40/sh20,000$2,288,000101,819 total
  • Exercise/Conversion

    Stock Option (Right to buy)

    2021-04-0610,000282,000 total
    Exercise: $1.16Exp: 2027-10-02Common Stock (10,000 underlying)
  • Exercise/Conversion

    Common Stock

    2021-04-06$1.16/sh+10,000$11,625111,819 total
  • Sale

    Common Stock

    2021-04-05$113.06/sh20,000$2,261,200101,819 total
  • Exercise/Conversion

    Stock Option (Right to buy)

    2021-04-0520,000292,000 total
    Exercise: $1.16Exp: 2027-10-02Common Stock (20,000 underlying)
  • Exercise/Conversion

    Common Stock

    2021-04-05$1.16/sh+20,000$23,250121,819 total
  • Exercise/Conversion

    Common Stock

    2021-04-01$1.16/sh+20,000$23,250121,819 total
  • Exercise/Conversion

    Stock Option (Right to buy)

    2021-04-0120,000312,000 total
    Exercise: $1.16Exp: 2027-10-02Common Stock (20,000 underlying)
Footnotes (5)
  • [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $109.00 to $113.03 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
  • [F2]Includes shares of common stock purchased under the Company's 2018 Employee Stock Purchase Plan.
  • [F3]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $111.24 to $115.90 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
  • [F4]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $112.06 to $116.25 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
  • [F5]On October 2, 2017, the Reporting Person was granted an option to purchase 392,000 ordinary shares pursuant to the Company's 2018 Equity Incentive Plan. The option vests as to one-fourth of the shares on October 2, 2018, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Issuer

Allakos Inc.

CIK 0001564824

Entity typeother

Related Parties

1
  • filerCIK 0001271905

Filing Metadata

Form type
4
Filed
Apr 5, 8:00 PM ET
Accepted
Apr 6, 8:00 PM ET
Size
21.2 KB